@article{183f4cde721c451ca8b4211eb97eb168,
title = "Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19",
keywords = "epidemiology, hydroxychloroquine, lupus erythematosus, pharmacokinetics, systemic",
author = "Konig, \{Maximilian F.\} and Kim, \{Alfred H.J.\} and Scheetz, \{Marc H.\} and Graef, \{Elizabeth R.\} and Liew, \{Jean W.\} and Julia Simard and MacHado, \{Pedro M.\} and Milena Gianfrancesco and Jinoos Yazdany and Daman Langguth and Robinson, \{Philip C.\}",
note = "Funding Information: Celltrion, unrelated to this manuscript. AHK received personal fees from Exagen Diagnostics, Inc and GlaxoSmithKline, unrelated to this manuscript. PMM received personal fees from Abbvie, Eli Lilly, Novartis and UCB Pharma. JY received personal fees from Astra Zeneca and Eli Lilly, unrelated to this manuscript. PCR reports personal fees from Abbvie, Pfizer, UCB Pharma, Novartis, Eli Lilly and Janssen, and non-financial support from Roche.",
year = "2020",
month = oct,
day = "1",
doi = "10.1136/annrheumdis-2020-217690",
language = "English",
volume = "79",
pages = "1386--1388",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
number = "10",
}